02410.HK
TYK Medicines, Inc
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.09
−2.22%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +16.4%
- EBIT
- +0.8%
- Net income
- +24.5%
- EPS
- +32.2%
- Free cash flow
- +33.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026